Ridgeline Therapeutics

11:30 AM - 11:45 AM (PDT), Wednesday, June 15, 2022
Ridgeline is entering FIH clinical trials to advance a transformative once-daily pill that restores muscle strength and function in all aging adults.
Company Type:
Privately Funded Company
Company HQ State:
Texas
Company HQ Country:
United States
Year Founded:
2014
Main Therapeutic Focus:
Lead Product in Development:
RT002
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
photo
CEO & Founder
Ridgeline Therapeutics